IDEXX Laboratories Inc Investor and Analyst Session Transcript
Good afternoon. Welcome to IDEXX's 2024 Investor and Analyst Session. I'm Jay Mazelsky, President and CEO of IDEXX, and a warm welcome to those of us who may be joining in the room and virtually through our webcast. It's a proud and great moment in IDEXX' history as we introduced the latest point-of-care analyzer to our VetLab family, the inVue Dx Cellular Analyzer.
Today's agenda, we have 45 minutes planned. Let me just spend a moment and set it up. It's going to be a combination of both prepared remarks from the leadership team as well as a brief question-and-answer session at the end. I'll kick it off. I'll provide an overview of the industry, the product opportunity, the clinical use cases and the impact we think we're going to have on practice productivity. I'll be followed by Dr. Martin Smith. He's our Chief Technology Officer. Dr. Smith will speak to the technical and clinical insights that have informed the product development process, leveraging our global pathology network that has produced (inaudible). Dr.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |